Gianna Dipalma | Medicine and Dentistry | Research Excellence Award

Prof. Dr. Gianna Dipalma | Medicine and Dentistry | Research Excellence Award

University of Bari “Aldo Moro” – University Hospital “Policlinico di Bari” | Italy

Prof. Gianna DiPalma is an accomplished clinician-scientist and academic specializing in dentistry, oral surgery, orthodontics, and regenerative medicine. With dual qualifications in Dentistry (DDS, 2000) and Medicine and Surgery (MD, 2020) from the University of Bari “Aldo Moro,” she has established a distinguished career bridging clinical practice, scientific innovation, and higher education. She further completed an international PhD program in Clinical Dentistry, conducted in collaboration with New York University (USA) and the Eastman Dental Institute (UK), followed by advanced postgraduate training in implant prosthodontics and oral surgical specialization. Her academic trajectory includes an international doctoral fellowship at the University of Lyon, France, reinforcing her international scientific profile. Prof. DiPalma has contributed extensively to oral health sciences, with research spanning regenerative dentistry, biomaterials, implantology, growth factor–based tissue repair, pediatric dentistry, and digital orthodontics. She has authored scientific publications, book chapters, and conference works, and serves as a reviewer and guest editor for internationally indexed journals, including Scopus- and PubMed-listed platforms. Her research involvement includes participation in competitive national and international projects, particularly those focusing on tissue engineering, stem cells, and translational dentistry. Her work demonstrates significant interdisciplinary relevance across dental medicine, biomedical engineering, and clinical innovation. Throughout her career, she has received more than 30 national and international awards recognizing academic merit, research contribution, and innovation in clinical dentistry. She has also contributed to the advancement of dental education through extensive teaching roles, postgraduate training supervision, and invited lectures across Europe and beyond. Prof. DiPalma’s contributions continue to support evidence-based innovations that improve patient care, guide clinical protocols, and enhance the global development of regenerative and digital dental sciences. Her academic trajectory reflects sustained research productivity, international collaboration, and a growing societal impact within the fields of oral health and medical sciences.

Profiles: Scopus | ORCID

Featured Publications

Buthelezi, K., Kibirige, D. M. K., & Buthelezi-Dube, N. N. (2025). The evolution of methods and tools used to assess soil health indicators: A scoping review. SSRN.

Buthelezi-Dube, N. N., & Sithole, Z. (2025). Acidification-driven soil phosphorus fractionation following long-term fertilization and cessation at Ukulinga mesic grassland in South Africa. Scientific Reports.

Buthelezi, K., & Buthelezi-Dube, N. (2025). Long-term effects of nitrogen and lime application on plant–microbial interactions and soil carbon stability in a semi-arid grassland. Plants.

Leshalagae, M., & Buthelezi-Dube, N. N. (2023). Impact of topsoil mining for unfired mudbricks on soil quality in eastern KwaZulu-Natal, South Africa. Land Degradation & Development.

Vilakazi, S. P., Muchaonyerwa, P., & Buthelezi-Dube, N. N. (2023). Characteristics and liming potential of biochar types from potato waste and pine-bark. PLOS ONE

Ricardo Salas Flores | Medicine and Dentistry | Global Health Impact Award

Dr. Ricardo Salas Flores | Medicine and Dentistry | Global Health Impact Award

Autonomous University of Tamaulipas | Mexico

Dr. Ricardo Salas Flores is an accomplished Pediatric Endocrinologist, clinical researcher, and academic leader with more than two decades of professional experience in pediatric endocrine disorders, diabetes, and obesity research. He currently serves as Principal Investigator at his research site, Dr. Ricardo Salas Flores Office (2011–present), and holds multiple academic roles including Full-Time Teacher and Professor of Endocrinology at the Faculty of Medicine “Dr. Alberto Romo Caballero,” Universidad Autónoma de Tamaulipas, Mexico. In addition, he serves as Clinical Health Education Coordinator and Associate Physician in Endocrinology at Hospital General No. 6 del IMSS in Ciudad Madero. Dr. Salas Flores earned a Medical Specialty in Pediatrics, followed by a Subspecialty in Pediatric Endocrinology and a Master of Medical Science from the Autonomous University of Tamaulipas. His professional qualifications are supported by national certifications, including Good Clinical Practice (CITI Program, 2020) and Digital Health Expert credentials. His clinical expertise spans metabolic disorders, pediatric diabetes, thyroid dysfunction, growth disorders, and endocrine-related chronic disease management. As a clinical researcher, Dr. Salas Flores has participated in multiple studies across Phase I to Phase IV clinical trial stages, with extensive experience in obesity-related research, including childhood obesity, fatty liver disease, and musculoskeletal health. His research scope also includes Type 1 and Type 2 diabetes, demonstrating a strong contribution to advancing endocrine care and supporting translational medical innovation. Dr. Salas Flores has collaborated with government programs, academic institutions, and industry partnerships to improve clinical practice and increase access to evidence-based endocrine care. His scientific work reflects a commitment to improving population health, strengthening pediatric care capacities, and advancing medical education in Mexico. Through his roles as educator, clinician, and researcher, he continues to mentor future healthcare professionals while contributing to the global medical community through research-driven medical practice.

Profiles: Scopus | ORCID

Featured Publications

Salas Flores, R. (2021). Alteraciones ultrasonográficas y funcionales hepáticas en niños y adolescentes con obesidad. Atención Familiar.

Salas Flores, R. (2021). Factores de riesgo asociados a retraso del crecimiento intrauterino. South Florida Journal of Development.

Salas Flores, R. (2021). Prevalencia de factores de riesgo que alteran la microbiota intestinal en niños escolares con sobrepeso y obesidad. South Florida Journal of Development.

Salas Flores, R. (2020). Conocimientos, actitudes y prácticas de los profesionales de la salud ante el VIH/SIDA en el primer nivel de atención. South Florida Journal of Development.

Salas Flores, R. (2020). Inercia terapéutica del médico familiar en pacientes con descontrol hipertensivo. South Florida Journal of Development.

Hsien-Hao Huang | Medicine and Dentistry | Excellence in Research Award

Assoc. Prof. Dr. Hsien-Hao Huang | Medicine and Dentistry | Excellence in Research Award

Institute of Emergency and Critical Care Medicine | Taiwan

Dr. Huang Hsien-Hao is an accomplished researcher and academic whose work spans advanced materials science, nanotechnology, and interdisciplinary engineering innovation. His scholarly contributions reflect a strong commitment to addressing global challenges through high-impact research, technological development, and international collaboration. Over the course of his career, Dr. Huang has established an impressive academic record, authoring numerous peer-reviewed publications in leading scientific journals and contributing to several book chapters and conference proceedings. His publications collectively demonstrate a consistent trajectory of innovation, with a citation profile that underscores the significance and global recognition of his work. Dr. Huang’s research expertise primarily focuses on functional materials, nanoscale fabrication, and the integration of advanced materials into biomedical, environmental, and energy-related applications. His work often bridges fundamental scientific principles with real-world applications, enabling solutions that enhance performance, sustainability, and societal well-being. Through his leadership in multidisciplinary projects, Dr. Huang has collaborated extensively with international research institutions, industry partners, and government-funded programs, contributing to breakthroughs in material performance, device efficiency, and next-generation engineering approaches. In recognition of his research excellence, Dr. Huang has received multiple awards, competitive grants, and professional honors. His contributions have not only advanced the academic understanding of his field but have also led to practical outcomes with wide-ranging societal impact, including improved material systems, enhanced diagnostic and therapeutic technologies, and environmentally conscious engineering solutions. He has also supervised graduate researchers, fostering the next generation of scientists and contributing to global scientific capacity building. Dr. Huang continues to play an influential role in the international scientific community through editorial duties, peer-review service, and active participation in conferences and professional societies. His ongoing work reflects a dedication to scientific advancement, innovation-driven research, and meaningful contributions to society.

Profiles: Scopus | ORCID

Featured Publications

  1. Predicting high-risk return at emergency department presentation for patients who undergo short-term revisits: The HANDLE-24 score. (2025). BMC Emergency Medicine.
  2. Association between intrinsic capacity and hospital admission among older adults in the emergency department. (2025). Journal of Applied Gerontology.
  3. Risk factors for mortality among patients with splenic infarction in the emergency department. (2025). Journal of the Formosan Medical Association.
  4. Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation. (2024). Journal of Cachexia, Sarcopenia and Muscle.
  5. The Clinical Frailty Scale is the significant predictor for in-hospital mortality of older patients in the emergency department. (2024). Letter.

 

Bo Wan | Medicine and Dentistry | Best Researcher Award

Dr. Bo Wan | Medicine and Dentistry | Best Researcher Award

Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Dr. Bo Wan is an emerging clinician–scientist in the field of ophthalmology, recognized for his strong commitment to advancing clinical practice and research related to myopia, cataract, and retinal disorders. With several years of experience as an ophthalmologist in a leading medical institution, he has developed extensive competence in the diagnosis, management, and surgical treatment of common and complex ocular diseases. His clinical work is characterized by precision, rigorous reasoning, and patient-centered decision-making, contributing to improved visual outcomes and enhanced quality of life for diverse patient populations. In parallel with his clinical responsibilities, Dr. Wan has maintained an active engagement in academic research, focusing on evidence-based approaches to ophthalmic disorders and exploring strategies for disease prevention and early intervention. He has authored 2 scholarly documents, which together have received 19 citations and an h-index of 1, reflecting the early but growing influence of his research contributions. His work demonstrates a consistent interest in the integration of clinical insights with scientific inquiry, and he has collaborated with colleagues across medical and academic settings to advance shared research goals. These collaborations have supported the development of multidisciplinary perspectives that enrich both clinical practice and investigative rigor. Dr. Wan’s scholarly activities reflect a broader commitment to public health and societal benefit. By contributing to improved diagnostic accuracy and more effective therapeutic pathways in ophthalmology, his work supports long-term visual health and addresses the rising global challenges of myopia and age-related ocular diseases. He is dedicated to continuous professional development and intends to expand his research output, strengthen international collaborations, and contribute to high-impact studies that can influence global ophthalmic guidelines and clinical standards. With a strong foundation in clinical practice, disciplined research habits, and a clear vision for future growth, Dr. Bo Wan is well positioned to make meaningful and sustained contributions to ophthalmic science and global eye health.

Profile: Scopus

Featured Publications

  1. (2024). Parallel comparison of ocular metrics in non-human primates with high myopia by LS900, ultrasonography and MRI-based 3D reconstruction. Experimental Eye Research.

 

Shaobing Hua | Medicine and Dentistry | Best Innovation Award

Prof. Dr. Shaobing Hua | Medicine and Dentistry | Best Innovation Award

Hangzhou Dalton Biosciences Ltd | China

Prof. Dr. Shaobing Hua is a distinguished biomedical scientist and innovator whose career spans more than three decades of impactful contributions to molecular biology, therapeutic antibody discovery, and advanced diagnostic technologies. Trained as a molecular biologist with postdoctoral experience at leading U.S. research institutions, he has played a pivotal role in translating fundamental discoveries into clinically deployable solutions. His early work advanced the understanding of signal transduction, proteasome regulation, and gene expression in protozoan parasites, laying the foundation for subsequent research in therapeutic antibody platforms, which led to multiple U.S. and international patents for novel humanized antibodies and high-throughput screening methods. Prof. Hua is widely recognized for developing next-generation hybrid capture technologies and innovative HPV testing platforms that have transformed cervical cancer screening, particularly in resource-limited settings. Under his scientific leadership, DALTON BioSciences has introduced a suite of diagnostic products for cervical cancer, endometrial carcinoma, pre-eclampsia, and vaginitis, contributing to the health of nearly 30 million women. His portfolio includes over 30 peer-reviewed publications in journals such as Journal of Biological Chemistry, Clinical Cancer Research, Protein Science, and Oncogene, and several dozens of patents granted in the United States, China, and the PCT system. His work has been cited widely by researchers across molecular diagnostics, oncology, and immunotechnology. Throughout his career, Prof. Hua has collaborated extensively with major clinical institutions, including leading hospitals affiliated with Zhejiang University, Peking University, the Chinese Academy of Medical Sciences, and several provincial oncology centers. He has served in key roles in national research programs, including China’s 863 Program, national key research plans, and major public health initiatives focused on cervical cancer elimination. His contributions have significantly advanced women’s health diagnostics, strengthened public health infrastructures, and accelerated the global adoption of innovative molecular screening technologies. Prof. Hua’s research, leadership, and translational impact continue to shape the future of precision diagnostics and global health innovation.

Profile: ORCID

Featured Publications

Liu, S., Han, B., Jin, D. Q., Li, L. W., Ge, T. T., Shou, Y. J., Ye, J. M., Zhang, L., & Hua, S. B. (2025). Design and development of a target amplification-free microfluidic platform for multiplex nucleic acids detection: A new generation of hybrid capture immunoassay. Journal of Medical Virology.

Ding, L., Lin, Y. H., Azam, M., Sheridan, J., Wei, S., Gupta, G., Singh, R. K., Pauling, M. H., Chu, A., Tran, A., Yu, N., Hu, J., Wang, W., Long, H., Xiang, D., Zhu, L., & Hua, S. B. (2010). Generation of high-affinity fully human anti-human interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Science, 19, 1957–1966.

Vaday, G. G., Hua, S. B., Peehl, D. M., Pauling, M. H., Lin, Y. H., Zhu, L., Lawrence, D. M., Foda, H. D., & Zucker, S. (2004). CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single-chain Fv antibodies. Clinical Cancer Research, 10, 5630–5639.

Xia, C., Ma, W., Wang, F., Hua, S. B., & Liu, M. (2001). Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene, 20, 5903–5907.

Xia, C., Bao, Z., Tabassam, F., Ma, W., Qiu, M., Hua, S. B., & Liu, M. (2000). GCIP, a novel human Grap2 and Cyclin D interacting protein, regulates E2F-mediated transcriptional activity. Journal of Biological Chemistry, 275, 20942–20948.

Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Dr. Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Sechenov University, Russia

Dr. Alexey Fayzullin, PhD, MD, is a distinguished medical scientist specializing in regenerative medicine, computational pathology, and digital biomedical technologies, with a strong academic and research foundation at Sechenov University, Russia. He completed his general medical studies at the International School “Medicine of the Future” (2011–2017) and earned his PhD in anatomical pathology in 2022, with a thesis on antifibrotic scaffolds in regenerative medicine. His professional journey began as a laboratory assistant (2018–2019) and junior researcher (2019–2023) in the Laboratory of Experimental Morphology at the Institute for Regenerative Medicine, before advancing to Head of the Laboratory of Digital Microscopic Analysis in 2023. His research interests span tissue engineering, artificial intelligence in histological image analysis, cell therapy, biophotonics, implantology, and computational biomedicine. With 47 peer-reviewed publications, 626 citations, and an h-index of 12, Dr. Fayzullin has contributed significantly to scientific knowledge, with his works appearing in internationally recognized journals and conferences. His research experience includes prestigious internships at Macquarie University and the University of New South Wales, where he collaborated on advanced bioengineering projects. He has won multiple competitive grants and awards, including several Russian Presidential Scholarships for international research, grants from the Russian Science Foundation (RSF) and Russian Foundation for Basic Research (RFBR), and the establishment of his own laboratory under the Priority 2030 program. His skills include advanced digital microscopy, AI-based image processing, regenerative scaffold design, project leadership, and academic mentoring. As an educator, he has co-authored Russia’s first regenerative medicine handbook, designed specialized academic courses, and supervises PhD and undergraduate students. Dr. Fayzullin’s honors, leadership roles, and international collaborations highlight his impact on both science and education. In conclusion, his remarkable achievements, innovative research, and commitment to biomedical advancement demonstrate why he is an emerging leader with the potential to shape the future of global regenerative medicine and digital healthcare.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022). Senescence-associated β-galactosidase detection in pathology. Diagnostics, 12(10), 2309. Cited 146 times

Shekhter, A. B., Fayzullin, A. L., Vukolova, M. N., Rudenko, T. G., Osipycheva, V. D., & Litvitsky, P. F. (2019). Medical applications of collagen and collagen-based materials. Current Medicinal Chemistry, 26(3), 506–516. Cited 129 times

Deng, W., McKelvey, K. J., Guller, A., Fayzullin, A., Campbell, J. M., Clement, S., & Saunders, C. M. (2020). Application of mitochondrially targeted nanoconstructs to neoadjuvant X-ray-induced photodynamic therapy for rectal cancer. ACS Central Science, 6(5), 715–726. Cited 88 times

Fayzullin, A., Bakulina, A., Mikaelyan, K., Shekhter, A., & Guller, A. (2021). Implantable drug delivery systems and foreign body reaction: Traversing the current clinical landscape. Bioengineering, 8(12), 205. Cited 73 times

Fayzullin, A., Churbanov, S., Ignatieva, N., Zakharkina, O., Tokarev, M., & Shekhter, A. (2021). Local delivery of pirfenidone by PLA implants modifies foreign body reaction and prevents fibrosis. Biomedicines, 9(8), 853. Cited 35

Shekhter, A. B., Pekshev, A. V., Vagapov, A. B., Telpukhov, V. I., Panyushkin, P. V., Fayzullin, A. L., & Vanin, A. F. (2019). Physicochemical parameters of NO-containing gas flow affect wound healing therapy: An experimental study. European Journal of Pharmaceutical Sciences, 128, 193–201. Cited 34

Giovanni Musso | Medicine and Dentistry | Best Researcher Award

Giovanni Musso | Medicine and Dentistry | Best Researcher Award

AOU San Luigi Gonzaga Orbassano (Torino), Italy

Dr. Giovanni Musso is a renowned clinician and researcher in Internal Medicine with a distinguished academic and professional career. He graduated in Medicine in 1996 with top honors (110/110) and completed his specialization in Internal Medicine in 2002 with distinction. Currently serving at the Department of Internal Medicine, Humanitas Gradenigo Hospital, Turin, he has devoted his career to the study of lipid and glucose metabolism, with particular emphasis on non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), and related metabolic complications. He leads international collaborative research involving 34 centers worldwide, producing high-impact findings on NAFLD epidemiology, pathogenesis, and staging, with publications in PLOS Medicine, Hepatology, Gastroenterology, BMJ, and other leading journals. His research interests include lipidomics, postprandial metabolism, gut microbiota, metabolic inflammation, and therapeutic innovations such as curcumin-based interventions and endoscopic approaches for metabolic disorders. His research skills span clinical trials, meta-analyses, translational studies, and consensus guideline development. Recognized globally, Dr. Musso has authored 101 documents, accrued 12,017 citations, and holds an impressive h-index of 49 (Sept 2025). His honors include co-authoring international consensus statements and leading global research collaborations. With his proven excellence in research, teaching, and clinical innovation, Dr. Musso continues to advance the field of hepatology and metabolic medicine while shaping future directions in precision healthcare.

Profile: ScopusORCID

Featured Publications

  • Musso, G., Mariano, F., Mella, A., Pinach, S., & Gambino, R. (2025, August 7). Meal-Induced NF-κB Activation in Mononuclear Cells Triggers Lumican Secretion and Promotes Chronic Kidney Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease. MedComm, 6(8), e70122.

  • Carpenito, N., Leporati, M., Sciarrillo, A., Pensa, A., Gambino, R., Musso, G., Mella, A., Biancone, L., Risso, D., Mariano, F., & Cosseddu, D. (2025, May 16). LC-MS/MS Determination of Quorum Sensing Molecules in Plasma from Burn Patients with Septic Shock Sustained by Acinetobacter baumannii. Antibiotics (Basel), 14(5), 517.

  • Musso, G., Mella, A., Mariano, F., Cassader, M., De Michieli, F., Riva, A., Petrangolini, G., Togni, S., Pinach, S., & Gambino, R. (2024). Impaired Postprandial GLP-2 Response Enhances Endotoxemia, Systemic Inflammation, and Kidney Injury in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Effect of Phospholipid Curcumin Meriva. Gut Microbes, 16(1), article 2424907.

  • Musso, G., Pinach, S., Mariano, F., Saba, F., De Michieli, F., Framarin, L., Berrutti, M., Paschetta, E., Parente, R., Lizet Castillo, Y., Leone, N., Castellino, F., Cassader, M., & Gambino, R. (2025, February 1). Effect of Phospholipid Curcumin Meriva® on Liver Histology and Kidney Disease in Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology, 81(2), 560–575.

  • Musso, G., Pinach, S., Saba, F., De Michieli, F., Cassader, M., & Gambino, R. (2024, July). Endoscopic Duodenal Mucosa Ablation Techniques for Diabetes and Nonalcoholic Fatty Liver Disease

 

Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Dr. Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Mary Bird Perkins Cancer Center | United States

Dr. Sotirios Stathakis is an accomplished medical physicist with extensive experience in radiation oncology, advanced treatment planning, and patient safety in cancer care. Currently serving as the Chief of Physics at Mary Bird Perkins Cancer Center and Adjunct Professor at Louisiana State University, he has established himself as a leader in both clinical and academic domains. His work bridges fundamental research and real-world clinical application, focusing on improving the accuracy, efficiency, and safety of radiotherapy treatments. With a career spanning over two decades, Dr. Stathakis has played a pivotal role in advancing technologies such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), Monte Carlo simulations, and adaptive radiotherapy. He has supervised graduate students, medical residents, and postdoctoral fellows, contributing to the development of the next generation of medical physicists. Dr. Stathakis is internationally recognized for his innovative contributions to medical physics, publishing widely in peer-reviewed journals and presenting at global conferences. His leadership in quality assurance (QA) protocols, radiotherapy safety standards, and patient-centered innovations has earned him professional recognition as a Fellow of the American Association of Physicists in Medicine (AAPM). He continues to expand his research by integrating artificial intelligence, patient education, and wearable technology into cancer care.

Professional Profile

Scopus | ORCID

Education

Dr. Sotirios Stathakis has a strong academic background rooted in physics and medical physics, which forms the foundation of his distinguished career in cancer treatment and research. He began his academic journey with a Bachelor of Science in Physics from the University of Waterloo, Canada, where he developed a strong foundation in core physical sciences and problem-solving skills. Driven by an interest in applying physics to medicine, he pursued a Master of Science in Medical Physics at the University of Aberdeen, United Kingdom. Here, he received specialized training in radiological sciences, medical imaging, and radiotherapy applications, which fueled his passion for research in patient care. His academic progression culminated in a Ph.D. in Medical Physics from the University of Patras, Greece, where his doctoral work focused on advanced radiation dosimetry and optimization of treatment planning systems. His doctoral training allowed him to explore Monte Carlo simulations and radiation safety protocols, which later became key aspects of his professional contributions. This comprehensive education, spanning North America and Europe, equipped him with a unique global perspective and multidisciplinary expertise. It also prepared him to integrate clinical practice with research, ultimately shaping his career as a recognized leader in medical physics and radiation oncology.

Professional Experience

Dr. Sotirios Stathakis has accumulated diverse professional experience that reflects his dual commitment to academic research and clinical application. He began his career in Europe, contributing to medical physics research before moving to the United States, where he established himself in leading academic and clinical institutions. At the University of Texas Health Science Center San Antonio (UTHSA), he served as a Professor and Medical Physicist, taking on responsibilities that included treatment planning, clinical implementation of new radiotherapy techniques, and the supervision of graduate students and medical residents. His academic contributions included teaching advanced courses in radiation oncology physics and mentoring Ph.D. dissertations. He later transitioned to his current role as Chief of Physics at Mary Bird Perkins Cancer Center, where he oversees medical physics operations across multiple oncology centers. In this role, he leads a team of physicists and ensures the safe and effective delivery of radiation treatments to cancer patients. His position as Adjunct Professor at Louisiana State University complements his clinical work, as he continues to teach and mentor the next generation of medical physicists. Throughout his career, Dr. Stathakis has balanced leadership, clinical service, and research, contributing to advancements in both patient care and academic knowledge.

Research Interests

Dr. Sotirios Stathakis’s research interests lie at the intersection of clinical innovation, radiation therapy optimization, and patient-centered approaches. A central focus of his research is the improvement of treatment planning systems, particularly through advanced modeling such as Monte Carlo simulations, which enhance accuracy in dose calculations. He has contributed to the development and refinement of quality assurance (QA) protocols, ensuring precision in intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Another important area of his research includes studying the secondary cancer risks associated with radiotherapy, providing valuable insights into long-term patient safety. Dr. Stathakis is also exploring the role of artificial intelligence (AI) in radiotherapy, particularly for dose prediction and workflow optimization, which has the potential to revolutionize clinical practices. In recent years, he has expanded his focus to include patient-centered technologies, such as wearable monitoring devices and virtual reality tools that improve patient education, engagement, and treatment compliance. His interdisciplinary approach combines physics, engineering, computer science, and clinical oncology, creating innovative solutions to complex healthcare challenges. By bridging these fields, Dr. Stathakis continues to advance the standards of radiotherapy, contributing to safer, more effective, and personalized cancer treatments.

Research Skills

Dr. Sotirios Stathakis possesses a broad range of research skills that span computational modeling, experimental validation, clinical trial design, and academic mentoring. His expertise in Monte Carlo simulations allows him to perform highly accurate radiation dose calculations, a critical aspect of treatment planning and safety assessment in radiation oncology. He is also highly skilled in advanced quality assurance techniques, particularly for IMRT and VMAT, ensuring reliable and precise delivery of radiation therapy. Dr. Stathakis is proficient in using and commissioning treatment planning systems and linear accelerators, applying both theoretical and practical approaches to improve clinical workflows. His research methodology incorporates statistical analysis, machine learning, and artificial intelligence, enabling him to address complex problems in treatment optimization and patient safety. Beyond technical skills, he excels in collaborative project management, coordinating interdisciplinary teams across physics, medicine, and engineering. His experience extends to academic publishing, peer review, and conference presentations, reflecting his ability to effectively disseminate scientific findings. As a mentor and educator, he has guided Ph.D. students and medical residents in developing independent research projects, further demonstrating his leadership in research environments. Collectively, these skills highlight his ability to translate advanced scientific concepts into practical innovations that benefit cancer patients worldwide.

Awards and Honors

Throughout his career, Dr. Sotirios Stathakis has received numerous awards and honors in recognition of his academic excellence, clinical leadership, and professional service. One of the most prestigious distinctions in his career is being named a Fellow of the American Association of Physicists in Medicine (AAPM), a recognition reserved for members who have made significant contributions to the advancement of medical physics. He is also board-certified in Therapeutic Radiologic Physics by the American Board of Radiology (ABR), underscoring his professional expertise and credibility in clinical practice. His academic work has been acknowledged through invitations to present at leading international conferences, including those organized by IEEE, AAPM, and ESTRO, where he has shared groundbreaking findings on radiotherapy optimization and quality assurance. In addition, Dr. Stathakis has served as a peer reviewer for high-impact journals such as the Journal of Applied Clinical Medical Physics (JACMP), further highlighting his standing in the scientific community. He has also been recognized by institutions where he has taught and worked, receiving commendations for excellence in mentorship and clinical service. These honors reflect his consistent commitment to innovation, patient safety, and education, solidifying his reputation as a respected leader in medical physics and radiation oncology.

Publication Top Notes

  • AAPM TG report 312: Acceptance testing, commissioning, and periodic quality assurance of ion chamber and diode detector arrays — 2025

  • Dosimetric characterization of a new surface-conforming electron MLC prototype — 2024 — 1 citation

  • Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc — 2022 — 5 citations

  • Erratum to: Report of AAPM Task Group 219 on independent calculation-based dose/MU verification for IMRT — 2021

  • Artificial intelligence based deconvolving on megavoltage photon beam profiles for radiotherapy applications — 2022

  • A customizable aluminum compensator system for total body irradiation — 2021

Conclusion

Dr. Sotirios Stathakis’s career represents a remarkable combination of academic excellence, clinical innovation, and professional leadership. His work has transformed multiple aspects of radiation oncology, from enhancing treatment planning accuracy to implementing robust quality assurance protocols that safeguard patient outcomes. With a strong foundation in education from top institutions across Canada, the United Kingdom, and Greece, coupled with his leadership roles in the United States, he exemplifies the global nature of medical physics. His research interests and skills reflect both scientific rigor and compassion, as he continually integrates patient-centered approaches into his innovations. Recognized internationally through awards, honors, and professional certifications, Dr. Stathakis has established himself as a trusted authority in his field. His mentorship of students and collaboration with clinicians ensure that his influence extends beyond his individual achievements, shaping the future of cancer care. Looking ahead, his engagement with artificial intelligence, wearable technology, and advanced radiotherapy models positions him to make further groundbreaking contributions. In sum, Dr. Stathakis embodies the qualities of a dedicated researcher, educator, and clinician, making him not only a leader in medical physics but also a driving force in advancing the fight against cancer globally.

Maria Kourti | Medicine and Dentistry | Best Researcher Award

Prof. Maria Kourti | Medicine and Dentistry | Best Researcher Award

Aristotle University of Thessaloniki | Greece

Prof. Maria Kourti is a distinguished academic and medical professional specializing in Pediatrics with a particular focus on Pediatric Hematology, Oncology, and Infectious Diseases. She currently serves as an Assistant Professor at Aristotle University of Thessaloniki, where she has been deeply involved in both teaching and research. Her career spans over two decades of excellence in clinical practice, scientific research, and international collaborations, with significant contributions to the understanding of childhood leukemia, drug resistance mechanisms, and pediatric infectious diseases. She has authored 73 publications indexed in PubMed, holds an h-index of 16, and has received over 1,000 citations, making her a recognized figure in her field. Prof. Kourti has combined clinical expertise with cutting-edge molecular and proteomic research, actively leading and participating in international multicenter studies and clinical trials. She is also extensively engaged in professional societies at the European and global levels, serving as a board member and committee leader in organizations dedicated to pediatric health. Alongside her academic achievements, she has contributed to medical education, mentorship, and health promotion initiatives, underlining her holistic approach to advancing both science and society. Her distinguished record makes her a highly respected leader in pediatric research and medicine.

Professional Profile

Scopus | ORCID 

Education

Prof. Maria Kourti pursued her entire academic journey at the Aristotle University of Thessaloniki, Greece, one of the most prestigious institutions in the country. She obtained her Medical Degree, laying the foundation for her career in pediatrics. With a strong interest in scientific research, she further advanced her education by earning a Master of Science (MSc) in Medical Research Technology, where she developed early expertise in biomedical investigations. Her passion for oncology and molecular medicine culminated in her Ph.D, with her thesis focused on the “Study of expression of multi-drug resistance genes in pediatric leukemia,” a topic that remains central to her research today. Her commitment to academic and clinical growth did not stop there, as she pursued advanced medical specialization, becoming Board Certified as a Specialist Pediatrician and later recognized as a Pediatric Infectious Disease Specialist. In the same year, she also completed a Post-Doctoral Fellowship in Proteomics in Childhood Leukemia, marking her continued dedication to translational research. This progression highlights her unique integration of medicine and science, equipping her with the academic depth and clinical expertise to make pioneering contributions in pediatric hematology, oncology, and infectious diseases.

Professional Experience

Prof. Maria Kourti has held several critical roles in clinical practice and academia, reflecting her dual expertise as a physician and researcher. she served as an Attending Physician in the Pediatric Oncology Department at Hippokration General Hospital, where she gained extensive clinical experience in treating children with hematological malignancies and solid tumors. Her expertise further deepened during her Pediatric Infectious Disease Fellowship at Aristotle University of Thessaloniki, based at Hippokration General Hospital. she worked as an Attending Physician in the 3rd Department of Pediatrics at Aristotle University, responsible for managing the Pediatric Hematology Unit, demonstrating her leadership in both patient care and academic responsibilities. she was appointed Assistant Professor of Pediatrics–Pediatric Hematology and Oncology at Aristotle University of Thessaloniki, where she continues to combine clinical duties with teaching and high-level research. Her responsibilities extend beyond the university, as she actively participates in national and international research programs, leading initiatives on childhood cancer, supportive care, and clinical trials. Through these roles, Prof. Kourti has developed a reputation for clinical excellence, academic leadership, and research innovation, making her a central figure in pediatric hematology and oncology in Greece and abroad.

Research Interests

Prof. Kourti’s research interests span the intersection of molecular biology, pediatric oncology, and infectious diseases, with a strong emphasis on improving treatment outcomes for children with cancer. Her doctoral and postdoctoral work centered on the molecular mechanisms of drug resistance in childhood leukemia, specifically the expression of multi-drug resistance genes and the application of proteomics to understand disease progression and treatment response. She has also been deeply engaged in genetic polymorphism studies, particularly in metabolic enzymes of carcinogenic substances in patients with acute leukemias and myelodysplastic syndromes. In addition to her oncology work, she has pursued significant research in pediatric infectious diseases, coordinating national efforts for the Greek Supportive Care Group and contributing to clinical research on antifungal therapies and novel antimicrobial strategies. Her interests also extend to large-scale clinical collaborations, where she has been both principal and sub-investigator in 15 multinational clinical trials addressing treatments for pediatric cancers and infections. This breadth of research demonstrates her commitment to translational medicine, bridging laboratory research with clinical applications. Her interests align with global health priorities, focusing on improving survival, reducing treatment toxicity, and enhancing supportive care in children with cancer.

Research Skills

Prof. Kourti possesses a strong foundation in molecular biology and clinical research methodologies, supported by advanced training and decades of practical application. Her technical expertise includes DNA and RNA extraction from blood and bone marrow samples, agarose gel electrophoresis, PCR, and RT-PCR, enabling her to investigate genetic and proteomic markers in pediatric leukemia. She has extensive experience with clinical trial design and implementation, having served as both a principal investigator and sub-investigator in numerous international studies, particularly within the SIOPE and SIOPEN networks. Her skills also extend to multidisciplinary collaboration, coordinating research teams across clinical and laboratory settings. In addition, Prof. Kourti has developed editorial and peer-review skills through her role as Guest Editor of special issues in international journals such as the Journal of Fungi and Diagnostics and as a reviewer for more than 10 medical journals. She also demonstrates expertise in data interpretation, publication writing, and conference presentation, with over 100 oral and poster presentations at national and international congresses. Her combined clinical and laboratory research skills, along with her organizational and editorial experience, make her a versatile and influential contributor to pediatric oncology and infectious disease research worldwide.

Awards and Honors

Throughout her career, Prof. Maria Kourti has received numerous awards and honors recognizing her excellence in research, teaching, and clinical practice. She has earned 10 major distinctions, including 3 scholarships from the National Scholarship Foundation (IKY), awarded for her academic performance and research potential. In addition, she has received 3 educational grants supporting her clinical and research training, as well as 6 first prizes for oral and poster presentations at both national and international medical congresses. These awards highlight not only her dedication to scientific inquiry but also her ability to effectively communicate her findings to diverse audiences. Beyond individual recognition, her leadership roles within professional societies such as the Hellenic Society for Social Pediatrics and Health Promotion, the National Pediatric Hematology and Oncology Society, and participation in European cooperative groups (SIOPE, ESPID, EXPeRT, ESCMID) further demonstrate the esteem in which she is held by the medical and scientific community. She has also contributed as a committee member for sustainability at ESPID, reflecting her commitment to long-term scientific advancement and ethical research practices. These honors collectively underscore her outstanding achievements and her influential role in pediatric medicine and research.

Publication Top Notes

  • Antifungal Use in Immunocompromised Children in Europe: A 12-Week Multicenter Weekly Point Prevalence Survey (CALYPSO) — 2025

  • A Global Analysis of Cases of Mucormycosis Recorded in the ECMM / ISHAM Zygomyco.net Registry from 2009 to 2022 — 2025

  • Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Research Network — 2025 — 3 citations

  • Addressing infectious challenges in pediatric cancer and hematopoietic cell transplantation: insights from the Umbrella Working Group — 2025

  • Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients — 2025

  • Planetary Health: What You Need to Know as a Pediatric Infectious Diseases Doctor — 2025

  • Successful Treatment of Disseminated Fusariosis in a 15-Month-old Boy With Refractory Acute Lymphoblastic Leukemia Using High-dose Voriconazole — 2024 — 1 citation

  • Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps — 2025

Conclusion

Prof. Maria Kourti exemplifies the qualities of a leading physician-scientist, with a career that integrates clinical expertise, innovative research, and academic leadership. Her groundbreaking work in childhood leukemia, infectious diseases, and pediatric oncology has advanced both scientific knowledge and clinical practice, directly impacting patient outcomes. With more than 73 peer-reviewed publications, extensive participation in international clinical trials, and leadership in national and European research groups, she has established herself as a key figure in the global pediatric research community. Her commitment to mentoring young scientists, active involvement in health promotion initiatives, and editorial contributions further enhance her academic profile. Looking ahead, Prof. Kourti is well-positioned to expand her research into global collaborations, increase her presence in high-impact journals, and take on greater leadership roles in shaping international pediatric oncology policies. Her career trajectory reflects not only past accomplishments but also significant potential for future contributions to medicine, making her a highly deserving candidate for continued recognition. In summary, Prof. Kourti’s lifelong dedication to advancing pediatric care and medical science positions her as an outstanding role model and leader in the field.

Pedro Antonio Regidor | Medicine and Dentistry | Best Researcher Award

Dr. Pedro Antonio Regidor | Medicine and Dentistry | Best Researcher Award

Medical Director from Exeltis Healthcare | Germany 

Dr. Pedro Antonio Regidor is a dual-national (Spanish and German) medical doctor and scientist with over three decades of clinical and leadership experience in the field of gynecology and obstetrics. He is currently the Medical Director of Exeltis Europe & Global Projects, overseeing pharmaceutical initiatives and innovations in women’s health across international markets. Dr. Regidor is a specialist in gynecological oncology, reproductive medicine, surgical gynecology, and perinatal care, and has performed thousands of complex surgeries and deliveries. His clinical expertise is reinforced by his academic contributions, having earned an MD in 1992 and a PhD in 2000 from the University of Essen. He has held several key roles in prominent German institutions such as the University of Essen, Westfälische Wilhelms-Universität Münster, and Klinikum Osnabrück. In addition, he has served in leadership roles within private medical consultancies and pharmaceutical companies. Dr. Regidor’s career reflects a dynamic integration of patient care, medical research, academic excellence, and corporate strategy. Through his work with Exeltis and affiliations with multiple scientific boards, he continues to shape the future of gynecological healthcare and pharmaceutical development on a global scale.

Professional Profile

Scopus Profile | ORCID Profile

Education

Dr. Regidor’s academic foundation is built on a robust medical and scientific education acquired in Germany. He earned his Doctor of Medicine (MD) on 21 March 1992, with a thesis focused on immunohistochemical detection of progesterone receptors in various tissues. His pursuit of advanced knowledge continued with a PhD in Gynecology and Obstetrics awarded by the University of Essen on 14 April 2000, based on research into peritoneal endometriosis. His studies not only demonstrated academic excellence but also provided the groundwork for his specializations in women’s health. Throughout his educational journey, he gained comprehensive training in multiple sub-disciplines, including endocrine disorders, surgical gynecology, and diagnostic imaging techniques such as mammography and hysterosalpingography. Dr. Regidor also pursued professional licensure in multiple countries, including Germany and Switzerland, reflecting his global perspective and adaptability in medical practice. He earned several professional qualifications between 1995 and 2006, officially recognized as a specialist in gynecology and obstetrics, gynecological endocrinology, reproductive medicine, and gynecological oncology. His academic credentials have empowered him to lead not only in clinical settings but also in the pharmaceutical and medical research sectors, demonstrating a lifelong commitment to education and advancement in medical science.

Professional Experience

Dr. Pedro Antonio Regidor has accumulated over 30 years of diverse professional experience, ranging from university hospitals and private clinics to high-level executive roles in the pharmaceutical industry. He began his medical career as a junior and medical resident at the University of Essen, focusing on gynecological oncology. His international exposure included a residency at Clínica Maternidad Concepción Palacios in Caracas, Venezuela, which enriched his global medical perspective. He later served as Assistant Medical Director in Essen and at Westfälische Wilhelms-Universität Münster, eventually becoming Chief of the Department of Gynecology and Obstetrics at Klinikum Osnabrück. Following years of leading hospital-based services, Dr. Regidor transitioned into private consultancy and pharmaceutical leadership roles. Since 2009, he has been affiliated with Frauenklinik München West and worked in executive medical roles for Velvian Germany GmbH and Exeltis. Currently, he is Medical Director of Exeltis Europe & Global Projects, managing international clinical and product development strategies. His career is distinguished by thousands of complex surgeries, strategic oversight of medical centers, and leadership in multinational pharmaceutical operations. His ability to bridge clinical knowledge with organizational leadership makes him a rare expert in both hands-on patient care and large-scale medical innovation.

Research Interests

Dr. Regidor’s research interests lie primarily in gynecological oncology, reproductive medicine, endocrinology, and women’s health diagnostics and therapeutics. He has a strong academic inclination toward understanding the pathophysiology of endometriosis, as evidenced by his PhD research on immunohistochemical investigations. He is particularly focused on the integration of clinical evidence with pharmacological innovation, developing solutions that address unmet needs in hormone replacement therapy, fertility regulation, and perinatal management. Through his leadership at Exeltis, he also explores new formulations of estrogen and progesterone therapies, especially in menopausal care and contraceptive technologies. Dr. Regidor is deeply invested in the development and validation of clinical protocols for surgical interventions, breast reconstruction, hormone diagnostics, and cancer therapy. He continues to engage in international collaborative research projects, particularly in clinical trials involving women’s hormone treatments and breast cancer. Additionally, he serves on scientific boards and advisory committees that drive research agendas in reproductive endocrinology and gynecological oncology. His work frequently intersects clinical application with scientific innovation, making him a key figure in translational medicine.

Research Skills

Dr. Regidor possesses a highly specialized skill set that encompasses both clinical research and surgical expertise. He is proficient in conducting immunohistochemical analyses, clinical trial coordination, and protocol development. His strong foundation in gynecological diagnostics allows him to interpret laboratory results with precision and apply them directly in surgical and medical decision-making. His surgical record is extensive, with over 7,000 procedures ranging from total laparoscopic hysterectomies to breast reconstructions, demonstrating exceptional hands-on expertise. In research contexts, he is adept at designing clinical studies, interpreting biomedical data, and ensuring ethical compliance across international sites. He has a deep understanding of hormonal pathways, disease modeling, and advanced imaging techniques, including radiological diagnostics for gynecologic applications. Dr. Regidor is also skilled in multilingual communication, enabling him to effectively collaborate on global research initiatives. Furthermore, his involvement with pharmaceutical companies has honed his abilities in regulatory science, medical writing, and strategic development of therapeutic pipelines. His combined skills in surgery, diagnostics, and clinical research make him a versatile asset in both academic and industry settings.

Awards and Honors

Over the course of his distinguished career, Dr. Pedro-Antonio Regidor has received numerous appointments and recognitions reflective of his impact in gynecology and medical leadership. While his career is not defined by traditional academic awards, his leadership roles themselves signify recognition by his peers and institutions. He served as Coordinator and Founding Member of the Breast Center in Münster, a pioneering initiative that contributed to Germany’s breast cancer diagnostic network. His repeated appointments as Medical Director at Velvian Germany GmbH and Exeltis Germany, Europe, and Global Projects further underscore his reputation as a trusted leader in the medical and pharmaceutical sectors. Additionally, he has been entrusted with consultancy roles for companies like Lipocine Inc. (USA) in the field of hormone therapy, showcasing global acknowledgment of his expertise. He holds membership in over ten professional societies, including the German Society for Gynecology and Obstetrics, West German Tumor Center, and scientific advisory boards related to endometriosis and reconstructive surgery. These positions not only validate his contributions but also recognize his ability to drive forward scientific agendas with clinical relevance.

Publications Top Notes

  • Effect over coagulation and fibrinolysis parameters of a prolonged-release contraceptive (2025) – Gynecological Endocrinology – 1 citation.

  • Prevalence of cumulative cardiovascular risk factors among French women of childbearing age: GYNRISK® survey (2025) – Journal of Gynecology Obstetrics and Human Reproduction – 1 citation.

  • Randomised trial comparing bleeding profiles of prolonged vs immediate-release contraceptives (2025) – European Journal of Contraception and Reproductive Health Care – 3 citations.

  • Anti-inflammatory effects of marine oil enriched with SPMs in Post-COVID Syndrome patients (2024) – Biomedicines – 4 citations.

  • Marine oil supplements during pregnancy to prevent preterm delivery (Review).

  • Omega-3 fatty acids and their role in pregnancy complications like preeclampsia and chorioamnionitis (Review)

Conclusion

Dr. Pedro-Antonio Regidor stands out as a multifaceted leader in gynecology, medical research, and pharmaceutical innovation. His extensive clinical experience, combined with a strong academic foundation and strategic leadership in the pharmaceutical industry, positions him uniquely at the intersection of science and healthcare delivery. He has made significant contributions to women’s health through his pioneering surgical interventions, research in reproductive medicine, and development of hormone-based therapies. His roles in clinical practice, academia, and corporate governance reflect a deep commitment to advancing medical science and improving patient care. Dr. Regidor’s work has positively impacted thousands of patients and influenced the direction of therapeutic innovation across Europe and beyond. With ongoing involvement in global projects and advisory boards, he is poised to further shape the landscape of gynecological healthcare and translational research. His career exemplifies excellence, leadership, and a tireless pursuit of medical advancement, making him a highly deserving candidate for recognition in international research and medical awards.